Solid tumor application creating expansion opportunity — the emerging clinical investigation of CD47 antagonism in solid tumors — where macrophage-mediated phagocytosis enhancement could address immune escape mechanisms in epithelial cancers beyond the hematologic malignancy focus — creating potential market expansion from hematologic indications' approximately 150,000 annual...